Cancer News and Research

Latest Cancer News and Research

Exact Sciences announces financial results for the third quarter ended Sept. 30, 2009

Exact Sciences Corp. today announced its financial results for the third quarter ended Sept. 30, 2009.

3 Nov 2009

Arrowhead Research updates its shareholders

Arrowhead Research Corporation’s (NASDAQ: ARWR) President and Chief Executive Officer today issued the following letter to the Company’s shareholders.

3 Nov 2009

Hetero bags 4 million dollar contract from Hard to Treat Diseases

Hard to Treat Diseases (HTDS; http://www.htdsmedical.com) Mellow Hope operating subsidiary is in process of finalizing contract details with Hetero Ltd., www.heterodrugs.com one of the largest pharmaceutical manufacturers in India. This contract has been in the works since March 2009, and its finalization promises solid sales boost for Hard to Treat Diseases.

3 Nov 2009

EntreMed to present its Aurora A/angiogenic kinase inhibitor data at the AACR-NCI-EORTC conference

EntreMed, Inc., a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer today announced presentations for its Aurora A/angiogenic kinase inhibitor, ENMD-2076, at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics to be held November 15-19, 2009 in Boston, Massachusetts. Presentations are listed below.

3 Nov 2009

Rigel Pharmaceuticals announces financial results for the third quarter of 2009

Rigel Pharmaceuticals, Inc. today reported financial results for the third quarter and nine months ended September 30, 2009.

3 Nov 2009

NIH awards $4 million research grant to AllTranz

AllTranz, Inc., a specialty pharmaceutical company focused on developing drugs to treat a variety of neurologic and inflammatory disorders, today announced that it has been awarded a $4 million research grant from the National Institute on Drug Abuse (NIDA), a component of the National Institutes of Health (NIH), to advance the company’s transdermal tetrahydrocannabinol (THC) patch for the treatment of marijuana dependence and withdrawal.

3 Nov 2009

SBRT stops the growth of cancer for 98% of patients with NSCLC

Stereotactic body radiation therapy (SBRT) stopped the growth of cancer at its original site in the lung for three years among nearly 98 percent of patients with early non-small cell lung cancer (NSCLC) who are unable to have the cancer surgically removed, according to an updated three-year study presented November 2, 2009, at the 51st Annual Meeting of the American Society for Radiation Oncology (ASTRO).

3 Nov 2009

New study to assess preventative brain radiation therapy for lung cancer patients

A new study is taking a closer look at the benefits versus risks for lung cancer patients to undergo preventative brain radiation therapy as a means to stop cancer from spreading to the brain.

3 Nov 2009

Melanoma patients treated with radiation after surgery at lower risk of cancer recurrence

High-risk melanoma patients who are treated with radiation after surgery have a significantly lower risk of their cancer returning to the lymph nodes (19 percent), compared to those patients who do not have radiation therapy (31 percent), according to the first randomized study of its kind presented at the plenary session, November 2, 2009, at the 51st Annual Meeting of the American Society for Radiation Oncology (ASTRO).

3 Nov 2009

Texas State University researchers to evaluate the effects of ALKA-V6 on animal organisms

Texas State University and Orizon Research Institute announced the signing of an agreement today that will permit University Researchers to continue efforts through in vivo testing to further determine the potential and effectiveness of ALKA-V6, a compound which has shown remarkable ability to kill cancer cells and inhibit the HIV virus in laboratory experiments.

3 Nov 2009

Symphogen announces the opening of its United States headquarters in Princeton

Symphogen A/S today announced the opening of its United States headquarters in Princeton, New Jersey. Adriann Sax, Symphogen’s recently appointed Chief Business Officer, will head the Company’s US business which will operate as Symphogen, Inc., a wholly-owned subsidiary of Symphogen A/S.

3 Nov 2009

World-record energies for laser accelerated particles achieved

An international team of physicists at Los Alamos National Laboratory has succeeded in using intense laser light to accelerate protons to energies never before achieved. Using this technique, scientists can now accelerate particles to extremely high velocities that would otherwise only be possible using large accelerator facilities. Physicists around the world are examining laser particle acceleration and laser produced radiation for potential future uses in cancer treatment.

3 Nov 2009

Two cancer-causing genes together can lead to aggressive leukaemia

Two genes, each one of which is known to cause cancer on its own, together can lead to aggressive leukaemia. This is the conclusion from new research carried out on gene-modified mice at the Sahlgrenska Academy at the University of Gothenburg, Sweden. The discovery has surprised scientists, and may lead to new treatments.

3 Nov 2009

Early tolerance of proton therapy excellent in prostate cancer patients

Proton beam therapy can be safely delivered to men with prostate cancer and has minimal urinary and rectal side effects, according to a study presented November 2, 2009, at the American Society for Radiation Oncology's 51st Annual Meeting in Chicago.

3 Nov 2009

Calypso Medical Technologies presents its real-time tracking technology at 51st ASTRO annual meeting

Calypso Medical Technologies, Inc., a developer of real-time localization technology used for the precise tracking of tumor targets, today announced Calypso’s real-time tracking technology is included in 36 scientific presentations and posters at the 51st Annual Meeting of the American Society for Therapeutic Radiation Oncology (ASTRO), now underway at McCormick Place in Chicago.

3 Nov 2009

A new blood test for breast cancer

A healthy 44-year-old woman will celebrate many future birthdays thanks to the efforts of Dr. Keri Sweeten and a new blood test for breast cancer

3 Nov 2009

Roche Applied Science to launch the NimbleGen CGX arrays in Europe and Japan

Roche Applied Science will announce the European and Asia Pacific launch of the NimbleGen CGX arrays for microarray-based cytogenetic analysis at a workshop series in four European cities and seven cities in Asia Pacific. The CGX arrays are designed by Signature Genomic Laboratories (Signature Genomics) and provide high-resolution, genome-wide analysis of chromosomal abnormalities.

3 Nov 2009

Medico's Hirata to distribute Broncus Technologies' LungPoint system and Yield catheters in Japan

Broncus Technologies, Inc., a medical device company focused on developing and commercializing innovative solutions for lung diseases, announced today at the American College of Chest Physicians CHEST 2009 meeting that it has entered into an exclusive agreement with Medico's Hirata as the sole distributor of their LungPoint system and Yield catheters in Japan.

3 Nov 2009

$Aggressive osteoporosis prevention could reduce hip fracture rate in the U.S. by 25%: Study$

Aggressive osteoporosis prevention could reduce hip fracture rate in the U.S. by 25%: Study

Aggressively managing patients at risk for osteoporosis could reduce the hip fracture rate in the United States by 25 percent, according to a Kaiser Permanente study published in the November issue of the Journal of Bone & Joint Surgery. The first step must be a more active role by orthopedic surgeons in osteoporosis disease management, researchers say.

3 Nov 2009

Siemens Healthcare to distribute Candelis' ImageGrid PACS-RT Appliance and ImageGrid RT Viewer

Today, Candelis, Inc. announced its plans to distribute and sell the ImageGrid™ PACS-RT Appliance and the ImageGrid™ RT Viewer through Siemens Healthcare’s Oncology Care Systems Business Unit.

3 Nov 2009

Cancer News and Research

Latest Cancer News and Research

Exact Sciences announces financial results for the third quarter ended Sept. 30, 2009

Arrowhead Research updates its shareholders

Hetero bags 4 million dollar contract from Hard to Treat Diseases

EntreMed to present its Aurora A/angiogenic kinase inhibitor data at the AACR-NCI-EORTC conference

Rigel Pharmaceuticals announces financial results for the third quarter of 2009

NIH awards $4 million research grant to AllTranz

SBRT stops the growth of cancer for 98% of patients with NSCLC

New study to assess preventative brain radiation therapy for lung cancer patients

Melanoma patients treated with radiation after surgery at lower risk of cancer recurrence

Texas State University researchers to evaluate the effects of ALKA-V6 on animal organisms

Symphogen announces the opening of its United States headquarters in Princeton

World-record energies for laser accelerated particles achieved

Two cancer-causing genes together can lead to aggressive leukaemia

Early tolerance of proton therapy excellent in prostate cancer patients

Calypso Medical Technologies presents its real-time tracking technology at 51st ASTRO annual meeting

A new blood test for breast cancer

Roche Applied Science to launch the NimbleGen CGX arrays in Europe and Japan

Medico's Hirata to distribute Broncus Technologies' LungPoint system and Yield catheters in Japan

Aggressive osteoporosis prevention could reduce hip fracture rate in the U.S. by 25%: Study

Siemens Healthcare to distribute Candelis' ImageGrid PACS-RT Appliance and ImageGrid RT Viewer

Cancer Research - Second Edition eBook

Innovating for impact: Jordi Labs on aligning methodologies with FDA expectation

Exploring the role of confocal-based high-content imaging in advancing core facilities

Transforming Cardiovascular Care: Insights from Mina Makar at AstraZeneca

Cancer News and Research

Latest Cancer News and Research

Cancer Research - Second Edition eBook

Innovating for impact: Jordi Labs on aligning methodologies with FDA expectation

Exploring the role of confocal-based high-content imaging in advancing core facilities

Transforming Cardiovascular Care: Insights from Mina Makar at AstraZeneca

Newsletters you may be interested in